GB2527477A - Tumour Therapy - Google Patents

Tumour Therapy Download PDF

Info

Publication number
GB2527477A
GB2527477A GB1518731.3A GB201518731A GB2527477A GB 2527477 A GB2527477 A GB 2527477A GB 201518731 A GB201518731 A GB 201518731A GB 2527477 A GB2527477 A GB 2527477A
Authority
GB
United Kingdom
Prior art keywords
components
prodrug
groups
disclosed
therapeutic system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1518731.3A
Other versions
GB201518731D0 (en
Inventor
Kenneth Dawson Bagshawe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB201518731D0 publication Critical patent/GB201518731D0/en
Publication of GB2527477A publication Critical patent/GB2527477A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

There is disclosed a therapeutic system comprising: (i) a prodrug; (ii) an enzyme that has an active site which is capable of converting the prodrug into a drug; (iii) a vascular-targeting agent; and (iv) an inhibitor which, following administration, reduces the level of enzyme activity. There is also disclosed a therapeutic system for the treatment of cancer employing the four components (i) - (iv) in which the four components are combined into two groups of components. The two groups of components may be formulated or modified such that one component is metabolically active before the other.
GB1518731.3A 2013-05-09 2014-04-30 Tumour Therapy Withdrawn GB2527477A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1308363.9A GB201308363D0 (en) 2013-05-09 2013-05-09 Tumour therapy
PCT/GB2014/051329 WO2014181085A1 (en) 2013-05-09 2014-04-30 Tumour therapy

Publications (2)

Publication Number Publication Date
GB201518731D0 GB201518731D0 (en) 2015-12-09
GB2527477A true GB2527477A (en) 2015-12-23

Family

ID=48672062

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1308363.9A Ceased GB201308363D0 (en) 2013-05-09 2013-05-09 Tumour therapy
GB1518731.3A Withdrawn GB2527477A (en) 2013-05-09 2014-04-30 Tumour Therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB1308363.9A Ceased GB201308363D0 (en) 2013-05-09 2013-05-09 Tumour therapy

Country Status (2)

Country Link
GB (2) GB201308363D0 (en)
WO (1) WO2014181085A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104817519B (en) * 2015-05-11 2016-11-16 中国药科大学 The derivant of one class CA-4, its preparation method and medical usage thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064065A2 (en) * 1998-06-11 1999-12-16 Enzacta R & D Limited Tumour therapy and imaging
US6015556A (en) * 1992-01-09 2000-01-18 Enzacta R & D Limited Cytotoxic drug therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
WO1993025197A1 (en) 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
GB9524942D0 (en) 1995-12-06 1996-02-07 Aepact Ltd Drug therapy
GB9624993D0 (en) 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
WO2000075164A1 (en) 1999-06-07 2000-12-14 Mirus Corporation COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
AU2002352162A1 (en) 2001-11-29 2003-06-10 Merck Patent Gmbh T-cell epitodes in carboxypeptidase g2
WO2011163594A2 (en) 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015556A (en) * 1992-01-09 2000-01-18 Enzacta R & D Limited Cytotoxic drug therapy
WO1999064065A2 (en) * 1998-06-11 1999-12-16 Enzacta R & D Limited Tumour therapy and imaging

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Research 59 (1999) 3998-4003 Pedley et al 'Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent' NLM10463598 *
Current Drug Targets 10 (2009) 152-157 Bagshawe 'Targeting: The ADEPT Story So Far' PREV200900180522 *

Also Published As

Publication number Publication date
GB201308363D0 (en) 2013-06-19
WO2014181085A1 (en) 2014-11-13
GB201518731D0 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2016007351A (en) Combination therapy for treating cancer.
EP4140487A8 (en) Combination therapy for treating cancer
MX2020010412A (en) Inhibitors of bruton's tyrosine kinase.
MX2020003174A (en) Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer.
MX2020004023A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia.
MX2016001793A (en) Combination therapy for the treatment of cancer.
SG10201902664RA (en) Combination therapy for treating cancer
MX2017017138A (en) Targeted conjugates of ksp inhibitors.
MX2015014591A (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer.
MX2015014599A (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer.
MX2017015896A (en) Anticancer agent.
MX2017005861A (en) Methods to target transcriptional control at super-enhancer regions.
MX2019013862A (en) Combination therapy.
MX2020001727A (en) Combination therapy.
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2017006076A (en) Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme.
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
MX2018004112A (en) Rational combination therapy for the treatment of cancer.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
GB2527477A (en) Tumour Therapy
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2015000473A (en) Combination of docosahexaenoic acid and indomethacin used as an analgesic.

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)